Literature DB >> 17095529

Third Belgian multicentre survey of antibiotic susceptibility of anaerobic bacteria.

Ingrid Wybo1, Denis Piérard, Inge Verschraegen, Marijke Reynders, Kristof Vandoorslaer, Geert Claeys, Michel Delmée, Youri Glupczynski, Bart Gordts, Margaretha Ieven, Pierrette Melin, Marc Struelens, Jan Verhaegen, Sabine Lauwers.   

Abstract

OBJECTIVES: To collect recent data on the susceptibility of anaerobes and to compare them with results from previous studies.
METHODS: Four hundred and forty-three anaerobic clinical isolates from various body sites were prospectively collected from October 2003 to February 2005 in nine Belgian hospitals. MICs were determined for nine anti-anaerobic and three recently developed antibiotics.
RESULTS: Most gram-negative bacilli except Fusobacterium spp. were resistant to penicillin. Piperacillin/tazobactam, metronidazole, chloramphenicol, meropenem and amoxicillin/clavulanic acid were very active against all groups, but only 86% of Bacteroides fragilis group strains were susceptible to the latter. Cefoxitin, cefotetan and clindamycin were less active. In particular, only 62%, 52% and 48% of B. fragilis group strains were susceptible, respectively. Clindamycin shows a continuing decrease in activity, as 83% were still susceptible in 1987 and 66% in 1993-94. Anti-anaerobic activity of the new antibiotics is interesting, with MIC50 and MIC90 of 1 and >32 mg/L for moxifloxacin, 2 and 4 mg/L for linezolid and 0.5 and 8 mg/L for tigecycline.
CONCLUSIONS: The susceptibility of anaerobic bacteria remains stable in Belgium, except for clindamycin, which shows a continuous decrease in activity. However, for each of the tested antibiotics, at least a few resistant organisms were detected. Consequently, for severe infections involving anaerobic bacteria, it could be advisable to perform microbiological testing instead of relying on known susceptibility profiles. Periodically monitoring background susceptibility remains necessary to guide empirical therapy.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17095529     DOI: 10.1093/jac/dkl458

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  21 in total

1.  Species identification of clinical Prevotella isolates by matrix-assisted laser desorption ionization-time of flight mass spectrometry.

Authors:  Ingrid Wybo; Oriane Soetens; Annelies De Bel; Fedoua Echahidi; Ellen Vancutsem; Kristof Vandoorslaer; Denis Piérard
Journal:  J Clin Microbiol       Date:  2012-02-01       Impact factor: 5.948

2.  Is the incidence of anaerobic bacteremia decreasing? Analysis of 114,000 blood cultures over a ten-year period.

Authors:  Lukas Fenner; Andreas F Widmer; Clarisse Straub; Reno Frei
Journal:  J Clin Microbiol       Date:  2008-05-07       Impact factor: 5.948

3.  Resistance trends of the Bacteroides fragilis group over a 10-year period, 1997 to 2006, in Madrid, Spain.

Authors:  Carmen Betriu; Esther Culebras; María Gómez; Fátima López; Iciar Rodríguez-Avial; Juan J Picazo
Journal:  Antimicrob Agents Chemother       Date:  2008-05-12       Impact factor: 5.191

4.  Canadian practice guidelines for surgical intra-abdominal infections.

Authors:  Anthony W Chow; Gerald A Evans; Avery B Nathens; Chad G Ball; Glen Hansen; Godfrey Km Harding; Andrew W Kirkpatrick; Karl Weiss; George G Zhanel
Journal:  Can J Infect Dis Med Microbiol       Date:  2010       Impact factor: 2.471

5.  Identification of clinically important anaerobic bacteria by an oligonucleotide array.

Authors:  Yu Tzu Lin; Mario Vaneechoutte; Ay Huey Huang; Lee Jene Teng; Hung-Mo Chen; Shu-Li Su; Tsung Chain Chang
Journal:  J Clin Microbiol       Date:  2010-02-03       Impact factor: 5.948

6.  Fusobacterial infections in children.

Authors:  Itzhak Brook
Journal:  Curr Infect Dis Rep       Date:  2013-06       Impact factor: 3.725

7.  Differentiation of cfiA-negative and cfiA-positive Bacteroides fragilis isolates by matrix-assisted laser desorption ionization-time of flight mass spectrometry.

Authors:  Ingrid Wybo; Annelies De Bel; Oriane Soetens; Fedoua Echahidi; Kristof Vandoorslaer; Marina Van Cauwenbergh; Denis Piérard
Journal:  J Clin Microbiol       Date:  2011-02-23       Impact factor: 5.948

Review 8.  Anaerobic infections: update on treatment considerations.

Authors:  Elisabeth Nagy
Journal:  Drugs       Date:  2010-05-07       Impact factor: 9.546

9.  Trends in the susceptibility of commonly encountered clinically significant anaerobes and susceptibilities of blood isolates of anaerobes to 16 antimicrobial agents, including fidaxomicin and rifaximin, 2008-2012, northern Taiwan.

Authors:  F D Wang; C H Liao; Y T Lin; W H Sheng; P R Hsueh
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2014-06-15       Impact factor: 3.267

10.  Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems.

Authors:  Chia-Ying Liu; Yu-Tsung Huang; Chun-Hsing Liao; Li-Ching Yen; Hsiu-Ying Lin; Po-Ren Hsueh
Journal:  Antimicrob Agents Chemother       Date:  2008-07-14       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.